Genetics and Weight Loss: New Insights from Recent Study
The surge in popularity of GLP-1 receptor agonists, a class of medications for weight loss, has brought valuable insights into how these drugs work differently for individuals. A recent study published in Nature explored the connection between genetics and the effectiveness of these drugs, particularly semaglutide and tirzepatide.
Researchers analyzed data from over 27,000 participants, focusing on self-reported weight loss and genetic information. They discovered a specific variation in the GLP-1 receptor gene (GLP1R) that appears to enhance the drug’s effectiveness. Those with this genetic variant lost an average of 1.6 pounds more than those without it.
One of the study’s authors, Noura Abul-Husn from the 23andMe Research Institute, remarked that this research advances the goal of a more personalized approach to weight management. However, the genetic boost is relatively small compared to the overall average weight loss of 24 pounds observed in the group.
In addition to genetic factors, traditional aspects such as age and sex were shown to be significant predictors of weight loss success. The study indicated that women achieved a greater reduction in body mass index (BMI)—12.2%—compared to a 10.0% reduction for men.
The findings also shed light on why some patients experience side effects such as nausea. Another genetic variant linked to increased reports of nausea and vomiting was identified. Notably, individuals with these variants still lost weight comparable to others; the side effects did not compromise the drug’s effectiveness.
Dr. Peter Balazs, a hormone and weight-loss expert, noted that the study points to the importance of genetic factors in treatment responses. He highlighted that different genetic variants affect how patients respond to specific medications. For instance, the variant causing nausea was linked to tirzepatide but not semaglutide.
However, there are limitations to the study. The data relied on participants self-reporting their weight, which could introduce bias. It lacked verification from medical records and did not include crucial information regarding treatment protocols or side effects.
Balazs emphasized that while the study raises intriguing possibilities about genetic testing and weight-loss medication choices, caution is needed before drawing definitive conclusions based solely on these findings.
Overall, this study marks a step toward understanding how genetics may play a role in weight management, paving the way for more tailored approaches in the future.
